Financial PerformanceValtecne is well positioned to meet the FY-25 top line expectation, with estimates, rating, and price target confirmed.
Growth StrategyThe appointment of Luigi Ferrari as a board member and senior advisor is expected to support Valtecne's growth through enhanced commercial strategy and international development.
Market GrowthThe Medical Devices division showed strong organic growth, driven by a buoyant orthopaedics market and increased product outflow related to VMI agreements.